JP7070137B2 - How to calculate the similarity of chromatograms - Google Patents

How to calculate the similarity of chromatograms Download PDF

Info

Publication number
JP7070137B2
JP7070137B2 JP2018117733A JP2018117733A JP7070137B2 JP 7070137 B2 JP7070137 B2 JP 7070137B2 JP 2018117733 A JP2018117733 A JP 2018117733A JP 2018117733 A JP2018117733 A JP 2018117733A JP 7070137 B2 JP7070137 B2 JP 7070137B2
Authority
JP
Japan
Prior art keywords
similarity
sample
section
chromatogram
measurement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018117733A
Other languages
Japanese (ja)
Other versions
JP2019219309A (en
Inventor
原一 植松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tosoh Corp
Original Assignee
Tosoh Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tosoh Corp filed Critical Tosoh Corp
Priority to JP2018117733A priority Critical patent/JP7070137B2/en
Publication of JP2019219309A publication Critical patent/JP2019219309A/en
Application granted granted Critical
Publication of JP7070137B2 publication Critical patent/JP7070137B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Description

本発明は、クロマトグラムの類似度の計算方法に関するものである。 The present invention relates to a method for calculating the similarity of chromatograms.

グルコースがヘモグロビンに結合したヘモグロビンA1c(HbA1c)の値は糖尿病の診断や治療において血糖状態を評価する指標として利用されている。HbA1cは過去1~2ヶ月の平均血糖値を反映しており、糖尿病患者における血糖コントロールマーカーとして有用である。 The value of hemoglobin A1c (HbA1c) in which glucose is bound to hemoglobin is used as an index for evaluating the blood glucose state in the diagnosis and treatment of diabetes. HbA1c reflects the average blood glucose level in the past 1 to 2 months and is useful as a blood glucose control marker in diabetic patients.

ヘモグロビン分子を構成するα鎖グロビンあるいはβ鎖グロビンのアミノ酸配列にアミノ酸置換、脱落、挿入がみられるものや、遺伝子融合による融合グロビン鎖を含んだもののように、その構成成分が通常とは異なるものは異常ヘモグロビンと呼ばれ、稀に存在することが知られている。このような検体を液体クロマトグラフィにより測定を行った場合、正常な検体とは異なる分離パターンを示すことが知られている。 Amino acid sequences of α-chain globin or β-chain globin that make up the hemoglobin molecule have amino acid substitutions, omissions, or insertions, or those containing fusion globin chains due to gene fusion, whose constituents are different from normal. Is called abnormal hemoglobin and is known to be rarely present. It is known that when such a sample is measured by liquid chromatography, it shows a separation pattern different from that of a normal sample.

また、分光分析の分野や質量分析の分野では、測定試料の特定/同定を目的として、「類似度」を用いた手法が頻繁に用いられている。これは比較対象となるスペクトルと、未知試料を測定して得られたスペクトルとを比較して、その類似性を数値で評価する手法である。x軸に波長または分子量をとって、それに対応した吸光度または強度をy軸とし、両者を比較し類似度計算に使用する。比較対象のデータのx軸、つまり、波長または分子量は、不確実性を含まないことが望まれる。 Further, in the fields of spectroscopic analysis and mass spectrometry, a method using "similarity" is frequently used for the purpose of identifying / identifying a measurement sample. This is a method of comparing the spectrum to be compared with the spectrum obtained by measuring an unknown sample and evaluating the similarity numerically. The wavelength or molecular weight is taken on the x-axis, and the corresponding absorbance or intensity is taken as the y-axis, and both are compared and used for similarity calculation. It is desirable that the x-axis of the data to be compared, that is, the wavelength or molecular weight, contains no uncertainty.

特許文献1は液体クロマトグラフィによるグリコヘモグロビンの分析に類似度の考えを適用し、クロマトグラムが正常であるか、異常であるかを判別する方法に適用した例である。グリコヘモグロビンの分離では、指標となるS-A1cピークの面積比率は全体の5%程度であり、90%程度はA0ピークで占められる。このような、不均等なクロマトグラムに対して類似度を計算すると、比率の高いA0ピークの形状の僅かな変化が、類似度の値を大きく変化させることになり、正確な指標とはならないという課題がある。 Patent Document 1 is an example of applying the idea of similarity to the analysis of glycohemoglobin by liquid chromatography and applying it to a method of determining whether a chromatogram is normal or abnormal. In the separation of glycohemoglobin, the area ratio of the S-A1c peak, which is an index, is about 5% of the whole, and about 90% is occupied by the A0 peak. When the similarity is calculated for such an uneven chromatogram, a slight change in the shape of the A0 peak with a high ratio will greatly change the similarity value, and it will not be an accurate index. There are challenges.

特開平9―251016号公報Japanese Unexamined Patent Publication No. 9-251016

本発明の課題は、グリコヘモグロビンを測定対象とした液体クロマトグラフィにおいて、取得されるクロマトグラムに基づく、測定試料と標準試料との類似度の計算方法を提供するものである。 An object of the present invention is to provide a method for calculating the degree of similarity between a measurement sample and a standard sample based on the obtained chromatogram in liquid chromatography using glycohemoglobin as a measurement target.

本発明に係るグリコヘモグロビンを測定対象とした液体クロマトグラフィにおいて、取得されるクロマトグラムに基づく、測定試料と標準試料との類似度の計算方法は、前記測定試料及び前記標準試料のクロマトグラムに対して、類似度計算を行う2以上の区間のドリフトを除去した後、各区間における両者の類似度を区間類似度として算出し、前記区間類似度に重みをもたせた平均値を、両者の最終的な類似度とすることを特徴とする。 In the liquid chromatography of glycohemoglobin according to the present invention, the method of calculating the similarity between the measurement sample and the standard sample based on the obtained chromatogram is based on the chromatogram of the measurement sample and the standard sample. After removing the drift of two or more sections for which similarity calculation is performed, the similarity between the two in each section is calculated as the section similarity, and the average value obtained by weighting the section similarity is the final value of both. It is characterized by having a degree of similarity.

また、本発明に係る計算方法の一態様においては、前記区間類似度への重みの設定方法を、クロマトグラムの成分ピークの強度を基に決定する。 Further, in one aspect of the calculation method according to the present invention, the method for setting the weight to the interval similarity is determined based on the intensity of the component peak of the chromatogram.

また、本発明に係る計算方法の一態様においては、前記区間類似度の計算を以下の式で算出する。 Further, in one aspect of the calculation method according to the present invention, the calculation of the section similarity is calculated by the following formula.

Figure 0007070137000001
Figure 0007070137000001

さらに、上述の計算方法で算出された両者の最終的な類似度が、任意の閾値以上となるか否かで、前記測定試料が正常か異常かを判断する方法を本発明は含んでいる。 Further, the present invention includes a method for determining whether the measured sample is normal or abnormal depending on whether or not the final similarity between the two calculated by the above calculation method is equal to or higher than an arbitrary threshold value.

また、前記測定試料として前記標準試料と同等の組成を有する試料を用いて、上述の計算方法で算出された両者の最終的な類似度が、任意の閾値以上となるか否かで、前記液体クロマトグラフィの装置異常の有無を判断する方法も本発明は含んでいる。 Further, using a sample having the same composition as the standard sample as the measurement sample, the liquid is determined by whether or not the final similarity between the two calculated by the above calculation method is equal to or higher than an arbitrary threshold value. The present invention also includes a method for determining the presence or absence of a chromatographic device abnormality.

本発明によれば、不均等なクロマトグラムであっても、区間ごとの類似度に重みをもたせた平均値を、測定試料と標準試料との最終的な類似度とするため、正確な指標を得ることができる。 According to the present invention, even if the chromatogram is uneven, the average value obtained by weighting the similarity for each section is used as the final similarity between the measurement sample and the standard sample, so that an accurate index can be used. Obtainable.

本発明におけるクロマトグラムのドリフト除去の効果を模式的に示した図である。It is a figure which showed the effect of the drift removal of the chromatogram in this invention schematically. 本発明における、類似度計算における時間区分を模式的に示した図である。It is a figure which showed schematically the time division in the similarity calculation in this invention. 実施例で用いたシステム構成を示した図である。It is a figure which showed the system configuration used in an Example. 実施例1の検証に使用した検体のクロマトグラムの一例を示した図である。It is a figure which showed an example of the chromatogram of the sample used for the verification of Example 1. FIG. (a)実施例1で用いた標準試料のクロマトグラム、(b)類似度計算の対象区間を示した図である。It is a figure which showed (a) the chromatogram of the standard sample used in Example 1, and (b) the target section of the similarity calculation. 実施例1での3区間の重み平均類似度の一覧を示した図である。It is a figure which showed the list of the weight average similarity of 3 sections in Example 1. FIG. 実施例1での3区間の単純平均類似度の一覧を示した図である。It is a figure which showed the list of the simple average similarity of 3 sections in Example 1. FIG. 実施例1での全区間を一つの区間とした類似度の一覧を示した図である。It is a figure which showed the list of the degree of similarity which made all the sections in Example 1 into one section. 実施例2での3区間の重み平均類似度の一覧を示した図である。It is a figure which showed the list of the weight average similarity of 3 sections in Example 2. FIG. 実施例2での全区間を一つの区間とした類似度の一覧を示した図である。It is a figure which showed the list of the degree of similarity which made all the sections in Example 2 into one section.

本発明の計算方法は、測定試料及び標準試料のクロマトグラムに対して、類似度計算を行う2以上の区間のドリフトを除去した後、各区間における両者の類似度を区間類似度として算出し、前記区間類似度に重みをもたせた平均値を、両者の最終的な類似度とするものである。以下、本発明の一実施形態について説明する。 In the calculation method of the present invention, after removing the drift of two or more sections for which similarity calculation is performed with respect to the chromatograms of the measurement sample and the standard sample, the similarity between the two in each section is calculated as the section similarity. The average value obtained by weighting the interval similarity is used as the final similarity between the two. Hereinafter, an embodiment of the present invention will be described.

なお、本発明における「クロマトグラム」とは、グリコヘモグロビンを測定対象とした液体クロマトグラフィにおいて、取得されるクロマトグラムを指す。また、標準試料のクロマトグラムを「基準クロマトグラム」、測定試料のクロマトグラムを「比較対象クロマトグラム」と言うことがある。 The "chromatogram" in the present invention refers to a chromatogram obtained in liquid chromatography using glycohemoglobin as a measurement target. Further, the chromatogram of the standard sample may be referred to as a "reference chromatogram", and the chromatogram of the measurement sample may be referred to as a "comparison target chromatogram".

類似度計算を行う区間のドリフトを除去する工程の一例としては、類似度計算を行う区間の開始点(x1、y1)及び終了点(x2、y2)[x:時間、y:出力]を決めて、直線式(y=ax+b)を算出し、クロマトグラムの各データ点(時間、出力)から前記直線式のy値を差し引く方法などが挙げられる。しかし、本工程はこの方法に限定されるものではない。開始点および終了点以外のピークが溶出していない複数の点を基に、多項式を算出し、クロマトグラムの各データ点(時間、出力)から前記多項式のy値を差し引く方法なども有用である。 As an example of the process of removing the drift of the section for which the similarity calculation is performed, the start point (x1, y1) and the end point (x2, y2) [x: time, y: output] of the section for which the similarity calculation is performed are determined. Then, a method of calculating a linear equation (y = ax + b) and subtracting the y value of the linear equation from each data point (time, output) of the chromatogram can be mentioned. However, this step is not limited to this method. It is also useful to calculate a polynomial based on a plurality of points where peaks other than the start point and the end point are not eluted, and subtract the y value of the polynomial from each data point (time, output) of the chromatogram. ..

本発明において、類似度計算を行う区間は2以上であるが、区間ごとに上述したような手順でドリフトを除去してもよく、複数の区間を含んだ範囲でドリフトを除去してもよい。例えば、開始点として測定開始点、終了点として測定終了点を指定すれば簡便なため、好適である(図1参照)。 In the present invention, the number of sections for which the similarity calculation is performed is two or more, but the drift may be removed by the procedure as described above for each section, or the drift may be removed in a range including a plurality of sections. For example, it is preferable to specify the measurement start point as the start point and the measurement end point as the end point because it is convenient (see FIG. 1).

ドリフトを除去した後、各区間における両者の類似度を区間類似度として算出する。グリコヘモグロビンのクロマトグラムでは、面積比率が健常人で5~6%程度であるS-A1c成分ピーク、面積比率が90%程度であるA0成分ピークを含んでいる。そのため、類似度計算を行う区間としては、S-A1c成分ピークを含む区間、A0成分ピークを含む区間、特異的に出現する成分ピークを含む区間の3つに分割することが好適である(図2参照)。また、類似度計算を行う区間は連続であっても、不連続であってもよい。 After removing the drift, the similarity between the two in each section is calculated as the section similarity. The chromatogram of glycohemoglobin contains an S—A1c component peak having an area ratio of about 5 to 6% and an A0 component peak having an area ratio of about 90%. Therefore, it is preferable to divide the section for calculating the similarity into three sections: a section including the S—A1c component peak, a section including the A0 component peak, and a section including the specifically appearing component peak (Fig.). 2). Further, the interval for which the similarity calculation is performed may be continuous or discontinuous.

「区間類似度」の計算方法は、式1で挙げるような方法が代表的であるが、波形の類似性の指標となれば良く、特に限定するものではない。式1を用いて計算される類似度は、最大で1000であり、1000に近いほど、同一性が高いことを示す。 The method for calculating the "interval similarity" is typically a method as described in Equation 1, but is not particularly limited as long as it can be used as an index of waveform similarity. The maximum similarity calculated using Equation 1 is 1000, and the closer it is to 1000, the higher the identity.

各区間における区間類似度を算出したら、前記区間類似度に重みをもたせた平均値を、測定試料と標準試料との最終的な類似度とする。重み係数を全て1あるいは同じ値にする「単純平均類似度」としても問題ないが、区間類似度に対する重み係数は、成分ピークの比率が小さい区間の係数を大きくし、成分ピークの比率が高い区間の係数を小さくすることで、比率の低い成分の変動に伴う類似度の変動を大きく見ることができるため、好ましい。 After calculating the interval similarity in each interval, the average value obtained by weighting the interval similarity is taken as the final similarity between the measurement sample and the standard sample. There is no problem even if the weighting coefficients are all 1 or the same value as "simple average similarity", but the weighting coefficient for the section similarity is the section where the ratio of the component peaks is small and the ratio of the component peaks is high. By reducing the coefficient of, it is preferable because the fluctuation of the similarity due to the fluctuation of the component having a low ratio can be seen large.

区間類似度への重みの設定方法としては、クロマトグラムの変化を明確に反映することを目的として、任意の重み係数を測定者が設定しても良い。また、クロマトグラムの成分ピークの強度を基に、つまり、強度の高いピークが含まれる区間の重みを小さくし、強度の低いピークが含まれる区間の重みを大きくしても良い。さらに、多種検体での平均的な区間毎の面積比率の逆数に応じて、区間の重みを決定することも良い(例えば第一区間面積比率:20%、第二区間面積比率:70%、第三区間面積比率:10%の場合、第一区間重み:3.5、第二区間重み:1.0、第三区間重み:7.0)。 As a method of setting the weight to the interval similarity, the measurer may set an arbitrary weight coefficient for the purpose of clearly reflecting the change in the chromatogram. Further, based on the intensity of the component peaks of the chromatogram, that is, the weight of the section including the high-intensity peak may be reduced, and the weight of the section including the low-intensity peak may be increased. Further, it is also possible to determine the weight of the section according to the inverse of the average area ratio for each section in various samples (for example, first section area ratio: 20%, second section area ratio: 70%, first. When the three-section area ratio: 10%, the first section weight: 3.5, the second section weight: 1.0, and the third section weight: 7.0).

上述した方法で得られた測定試料と標準試料との最終的な類似度は、任意の閾値以上となるか否かで、測定試料が正常か異常かを判断することが可能である。また、測定試料として標準試料と同等の組成を有する試料を用いれば、すなわち標準試料同士のクロマトグラムに対して類似度計算を行えば、任意の閾値以上となるか否かで、測定に用いた液体クロマトグラフィの装置異常の有無を判断することも可能である。 It is possible to judge whether the measurement sample is normal or abnormal depending on whether or not the final similarity between the measurement sample obtained by the above method and the standard sample is equal to or higher than an arbitrary threshold value. In addition, if a sample having the same composition as the standard sample is used as the measurement sample, that is, if the similarity is calculated for the chromatograms of the standard samples, it is used for the measurement depending on whether or not it exceeds an arbitrary threshold value. It is also possible to determine the presence or absence of an abnormality in the liquid chromatography device.

以下に実施例を示し、本発明の実施の形態についてさらに詳しく説明する。もちろん、本発明は以下の実施例に限定されるものではなく、細部については様々な態様が可能であることはいうまでもない。さらに、本発明は上述した実施形態に限定されるものではなく、請求項に示した範囲で種々の変更が可能であり、それぞれ開示された技術的手段を適宜組み合わせて得られる実施形態についても本発明の技術的範囲に含まれる。また、本明細書中に記載された文献の全てが参考として援用される。 Examples are shown below, and embodiments of the present invention will be described in more detail. Of course, the present invention is not limited to the following examples, and it goes without saying that various aspects are possible for details. Furthermore, the present invention is not limited to the above-described embodiment, and various modifications can be made within the scope of the claims, and the present invention also relates to an embodiment obtained by appropriately combining the disclosed technical means. It is included in the technical scope of the invention. In addition, all of the documents described in this specification are incorporated by reference.

図3に示すシステムを使用し、実際の測定を行った。グリコヘモグロビン分析計は東ソー(株)製HLC-723G8および専用のカラム、溶離液を使用した。なお、測定モードは異常ヘモグロビン種の特定が容易とされる「バリアントモード」で行った。
異なる3種の溶離液(1、2、3)を指定した時間で切り替え、分析カラム(10)へ送液することで、注入された試料を、溶出力を変えて各々の成分に分離し、可視検出器(12)でその量を計測するものである。なお、試料注入装置(8)は、採血管で採取された全血をそのまま自動で溶血/希釈し注入すること、および標準試料やコントロール試料のような希釈検体も注入できる構成となっている。
The actual measurement was performed using the system shown in FIG. The glycohemoglobin analyzer used HLC-723G8 manufactured by Tosoh Corporation, a dedicated column, and an eluent. The measurement mode was "variant mode", which makes it easy to identify abnormal hemoglobin species.
By switching between three different eluents (1, 2, 3) at a specified time and sending the solution to the analysis column (10), the injected sample is separated into each component by changing the dissolution output. The amount is measured by the visible detector (12). The sample injection device (8) is configured to automatically hemolyze / dilute and inject the whole blood collected in the blood collection tube as it is, and to inject a diluted sample such as a standard sample or a control sample.

(実施例1)
本実施例では、クロマトグラムの同一性判断により正常な検体と異常ヘモグロビン種が識別できるか検証を行った。
正常検体(10検体、うち1検体を標準試料とした)、HbAlcキャリブレータ(Level1、2 東ソー(株)製)、HbAlcコントロール(Level1、2 東ソー(株)製)、および、前記正常検体にバリアントヘモグロビンコントロール2種を添加した検体(28検体)を使用して評価を実施した。なお、前記バリアントヘモグロビンコントロールはAnalytical Control Systems社製、バリアントヘモグロビンコントロールAS(HC-104)、およびバリアントヘモグロビンコントロールAC(HC-105)を使用した。また、臨床的に測定された異常ヘモグロビン検体(29検体)のクロマトグラムも併せて評価した。
以上の検体を測定し、クロマトグラムを取得し、測定開始点および測定終了点でドリフト除去処理を施した。
(Example 1)
In this example, it was verified whether a normal sample and an abnormal hemoglobin species could be distinguished by determining the identity of the chromatogram.
Normal sample (10 samples, 1 of which was used as the standard sample), HbAlc calibrator (Level1, 2 Tosoh Co., Ltd.), HbAlc control (Level1, 2 Tosoh Co., Ltd.), and variant hemoglobin to the normal sample. Evaluation was performed using a sample (28 samples) to which 2 types of controls were added. As the variant hemoglobin control, Variant Hemoglobin Control AS (HC-104) and Variant Hemoglobin Control AC (HC-105) manufactured by Analytical Control Systems, Inc. were used. In addition, chromatograms of clinically measured abnormal hemoglobin samples (29 samples) were also evaluated.
The above samples were measured, chromatograms were obtained, and drift removal processing was performed at the measurement start point and measurement end point.

図4に(a)正常検体、(b)バリアントヘモグロビンコントロールAS(HC-104)添加検体、(c)バリアントヘモグロビンコントロールAC(HC-105)添加検体のクロマトグラムを示す。
本実施例では、クロマトグラムの特徴の変化が顕著に表れると想定される第一区間(0.0分~0.7分)、第二区間(0.7分~1.0分)、第三区間(1.0分~1.6分)の3つの区間に分割して区間類似度を算出した(図5(b)参照)。なお、第一区間はS-A1cピークを含む時間領域、第二区間はA0ピークを含む時間領域、第三区間は異常ヘモグロビン種の成分ピークが出現しやすい時間領域である。重み係数は、第一区間を2、第二区間を1、第三区間を3とした。すなわち、区間類似度に区間ごとの重み係数(1、2、3)を掛けた値の合計を、重み係数の総和(1+2+3)で除した値を重み平均類似度とした。
FIG. 4 shows chromatograms of (a) normal sample, (b) variant hemoglobin control AS (HC-104) -added sample, and (c) variant hemoglobin control AC (HC-105) -added sample.
In this example, the first section (0.0 minutes to 0.7 minutes), the second section (0.7 minutes to 1.0 minutes), and the first section, where changes in the characteristics of the chromatogram are expected to appear significantly. The section similarity was calculated by dividing into three sections (1.0 to 1.6 minutes) (see FIG. 5 (b)). The first section is a time domain including the S—A1c peak, the second section is the time domain including the A0 peak, and the third section is the time domain in which the component peak of the abnormal hemoglobin species is likely to appear. The weighting coefficient was 2 for the first section, 1 for the second section, and 3 for the third section. That is, the value obtained by dividing the sum of the values obtained by multiplying the interval similarity by the weighting coefficient (1, 2, 3) for each interval by the sum of the weighting coefficients (1 + 2 + 3) was defined as the weight average similarity.

図6に3区間の重み平均類似度、図7に3区間の単純平均類似度の結果一覧を示す。いずれの計算方法でも、正常検体と異常ヘモグロビン種との間では優位差が見られるが、重み平均類似度での結果の方が、その差がより明確になっている。一方、全区間を一つの区間として類似度計算を実施した場合、図8の如く、正常検体と異常ヘモグロビン種の区別ができない所が多々出てくる。なお、図中の「N」は正常検体、「+(1)」は正常検体にHC-104を添加した検体、「+(2)」は正常検体にHC-105を添加した検体、「U」は異常ヘモグロビン検体を示している。 FIG. 6 shows a list of the results of the weight average similarity of the three sections, and FIG. 7 shows a list of the results of the simple average similarity of the three sections. In both calculation methods, there is a dominant difference between the normal sample and the abnormal hemoglobin species, but the difference is clearer in the results with the weight average similarity. On the other hand, when the similarity calculation is performed with all the sections as one section, there are many places where it is not possible to distinguish between the normal sample and the abnormal hemoglobin species as shown in FIG. In the figure, "N" is a normal sample, "+ (1)" is a sample obtained by adding HC-104 to a normal sample, and "+ (2)" is a sample obtained by adding HC-105 to a normal sample, "U". "Indicates an abnormal hemoglobin sample.

単純平均類似度の計算の場合、類似度の閾値を900程度、重み平均類似度の計算の場合は、類似度の閾値をより低い850程度に設定しても、明確に正常検体と異常ヘモグロビン種検体のクロマトグラムの区別ができる。 In the case of simple average similarity calculation, the threshold of similarity is set to about 900, and in the case of calculation of weighted average similarity, even if the threshold of similarity is set to about 850, which is lower, the normal sample and abnormal hemoglobin species are clearly defined. The chromatogram of the sample can be distinguished.

(実施例2)
本実施例では、クロマトグラムの同一性判断により測定装置の異常(流量の変動)が検出できるか検証を行った。
試料として正常検体(Sample_A)と、前記正常検体にバリアントヘモグロビンコントロール2種を添加した検体(Sample_I、J)も併せて使用した。なお、前記バリアントヘモグロビンコントロールはAnalytical Control Systems社製、バリアントヘモグロビンコントロールAS(HC-104)、およびバリアントヘモグロビンコントロールAC(HC-105)を使用した。
標準的な測定時の流量ファクター(流量の相対値)は1.00で運用され、0.98~1.02であれば正常な測定が行えると言える。ファクターを1.00、1.02、1.04、1.06、0.98、0.96、0.94で測定を実施し、装置異常の有無について閾値を類似度850と設定した。本実施例ではファクターを1.00で測定した正常検体Sample_Aの結果を基準クロマトグラム(標準試料)とし、類似度を算出する時間区分及び重み係数等の条件は実施例1と同様とした。
(Example 2)
In this example, it was verified whether or not an abnormality (fluctuation in flow rate) of the measuring device could be detected by judging the identity of the chromatogram.
As a sample, a normal sample (Sample_A) and a sample (Sample_I, J) in which two variants of hemoglobin control were added to the normal sample were also used. As the variant hemoglobin control, Variant Hemoglobin Control AS (HC-104) and Variant Hemoglobin Control AC (HC-105) manufactured by Analytical Control Systems, Inc. were used.
The flow rate factor (relative value of the flow rate) at the time of standard measurement is operated at 1.00, and it can be said that normal measurement can be performed if it is 0.98 to 1.02. Measurements were performed with factors of 1.00, 1.02, 1.04, 1.06, 0.98, 0.96, and 0.94, and a threshold value of similarity 850 was set for the presence or absence of device abnormality. In this example, the result of the normal sample Sample_A whose factor was measured at 1.00 was used as a reference chromatogram (standard sample), and the conditions such as the time division for calculating the similarity and the weighting coefficient were the same as in Example 1.

図9に3区間の重み平均類似度の結果一覧、図10に全区間を一つの区間とした類似度の結果一覧を示す。
図9から分かるように、3区間重み平均類似度では、流量ファクターが1.00で測定したSample_A、I、Jの3種で2つのグループが存在していることが見てとれる。そして、流量ファクター0.98、1.00、1.02で測定を行った場合、Sample_Aの類似度は850以上となったが、それ以外の流量ファクターで測定を行った場合は、Sample_Aの類似度は850未満であり、装置異常の判断が正常に行われていることが確認できた。
一方、図10から分かるように、全区間を一つの区間として計算した場合の類似度では、例えば、流量ファクターが1.00で測定したSample_A、I、Jの3種で殆ど差異が見られない。そして、流量ファクター1.02で測定を行った場合、Sample_Aの類似度は850未満となり、装置異常と判断されてしまった。
FIG. 9 shows a list of results of weight average similarity of three sections, and FIG. 10 shows a list of results of similarity with all sections as one section.
As can be seen from FIG. 9, in the three-interval weight average similarity, it can be seen that there are two groups of three types of Sample_A, I, and J measured at a flow rate factor of 1.00. When the measurement was performed with the flow rate factors of 0.98, 1.00, and 1.02, the similarity of Sample_A was 850 or more, but when the measurement was performed with other flow rate factors, the similarity of Sample_A was similar. The degree was less than 850, and it was confirmed that the determination of the device abnormality was performed normally.
On the other hand, as can be seen from FIG. 10, in the similarity when all the sections are calculated as one section, for example, there is almost no difference between the three types of Sample_A, I, and J measured at a flow rate factor of 1.00. .. Then, when the measurement was performed with the flow rate factor of 1.02, the similarity of Sample_A was less than 850, and it was determined that the device was abnormal.

1.第一溶離液
2.第二溶離液
3.第三溶離液
4.溶血洗浄液
5.脱気装置
6.電磁弁
7.送液ポンプ
8.試料注入機構
9.プレフィルタ
10.分析カラム
11.抵抗管
12.可視吸収検出器
13.恒温槽
14.検体
15.廃液
1. 1. First eluent 2. Second eluent 3. Third eluent 4. Hemolytic cleaning solution 5. Deaerator 6. Solenoid valve 7. Liquid feed pump 8. Sample injection mechanism 9. Pre-filter 10. Analytical column 11. Resistance tube 12. Visible absorption detector 13. Constant temperature bath 14. Specimen 15. Waste liquid

Claims (5)

グリコヘモグロビンを測定対象とした液体クロマトグラフィにおいて、
取得されるクロマトグラムに基づく、測定試料と標準試料との類似度の計算方法であって、
前記測定試料及び前記標準試料のクロマトグラムに対して、
類似度計算を行う2以上の区間のドリフトを除去した後、
各区間における両者の類似度を区間類似度として算出し、
前記区間類似度に重みをもたせた平均値を、両者の最終的な類似度とする前記方法。
In liquid chromatography using glycohemoglobin as a measurement target,
It is a method of calculating the similarity between the measurement sample and the standard sample based on the obtained chromatogram.
For the chromatograms of the measurement sample and the standard sample
After removing the drift of two or more sections for similarity calculation,
The similarity between the two in each section is calculated as the interval similarity, and
The method in which the average value obtained by weighting the interval similarity is used as the final similarity between the two.
前記区間類似度への重みの設定方法が、クロマトグラムの成分ピークの強度を基に決定することを特徴とする請求項1に記載の方法。 The method according to claim 1, wherein the method for setting the weight to the interval similarity is determined based on the intensity of the component peak of the chromatogram. 前記区間類似度の計算を以下の式で算出することを特徴とする請求項1又は2に記載の方法。
Figure 0007070137000002
The method according to claim 1 or 2, wherein the calculation of the interval similarity is calculated by the following formula.
Figure 0007070137000002
請求項1~3のいずれかに記載の方法で算出された両者の最終的な類似度が、任意の閾値以上となるか否かで、前記測定試料が正常か異常かを判断する方法。 A method for determining whether the measurement sample is normal or abnormal depending on whether or not the final similarity between the two calculated by the method according to any one of claims 1 to 3 is equal to or higher than an arbitrary threshold value. 前記測定試料として前記標準試料と同等の組成を有する試料を用いて、請求項1~3のいずれかに記載の方法で算出された両者の最終的な類似度が、任意の閾値以上となるか否かで、前記液体クロマトグラフィの装置異常の有無を判断する方法。 Whether the final similarity between the two calculated by the method according to any one of claims 1 to 3 using a sample having the same composition as the standard sample as the measurement sample is equal to or higher than an arbitrary threshold value. A method for determining the presence or absence of an abnormality in the liquid chromatography apparatus.
JP2018117733A 2018-06-21 2018-06-21 How to calculate the similarity of chromatograms Active JP7070137B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018117733A JP7070137B2 (en) 2018-06-21 2018-06-21 How to calculate the similarity of chromatograms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018117733A JP7070137B2 (en) 2018-06-21 2018-06-21 How to calculate the similarity of chromatograms

Publications (2)

Publication Number Publication Date
JP2019219309A JP2019219309A (en) 2019-12-26
JP7070137B2 true JP7070137B2 (en) 2022-05-18

Family

ID=69096282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018117733A Active JP7070137B2 (en) 2018-06-21 2018-06-21 How to calculate the similarity of chromatograms

Country Status (1)

Country Link
JP (1) JP7070137B2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017194349A (en) 2016-04-20 2017-10-26 アークレイ株式会社 Method, device, and program for measuring glycated hemoglobin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0437829B1 (en) * 1990-01-18 1994-10-05 Hewlett-Packard Company Method for distinguishing mixtures of chemical compounds
JP3572327B2 (en) * 1996-03-15 2004-09-29 東ソー株式会社 Data processing method for diagnostic equipment using liquid chromatography

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017194349A (en) 2016-04-20 2017-10-26 アークレイ株式会社 Method, device, and program for measuring glycated hemoglobin

Also Published As

Publication number Publication date
JP2019219309A (en) 2019-12-26

Similar Documents

Publication Publication Date Title
JP6780290B2 (en) Measurement method of glycated hemoglobin and glycated hemoglobin measuring device
US10935526B2 (en) Liquid chromatograph and method for correcting detector output value fluctuation of liquid chromatograph
EP3221693B1 (en) A method and apparatus for performing liquid chromatography purification
JP5948727B2 (en) Method for measuring glycated hemoglobin and apparatus for measuring glycated hemoglobin
Puchwein Selection of calibration samples for near-infrared spectrometry by factor analysis of spectra
EP2447712A2 (en) Calibration method in measurement of hemoglobin A1c
CN113167776B (en) Sample measurement device and measurement parameter setting support device
CN117607277A (en) Blank run analysis of chromatographic performance
Herpol et al. Evaluation of the Sebia Capillarys 3 Tera and the Bio-Rad D-100 systems for the measurement of hemoglobin A1c
Rodriguez-Capote et al. Identification of Hb Wayne and its effects on HbA1c measurement by 5 methods
JP7070137B2 (en) How to calculate the similarity of chromatograms
JP3496390B2 (en) Data processing method for glycated hemoglobin measuring device using liquid chromatography
JP7081385B2 (en) How to calculate the similarity of chromatograms
JP3572327B2 (en) Data processing method for diagnostic equipment using liquid chromatography
JP7119602B2 (en) How to calculate chromatogram similarity
JP7067189B2 (en) Data processing method in glycohemoglobin analysis
Doggui et al. Capillarys 2 Flex Piercing: analytical performance assessment according to CLSI protocols for HbA1c quantification
Gosselin et al. Comparison of the BioRad Variant and Primus Ultra2 high‐pressure liquid chromatography (HPLC) instruments for the detection of variant hemoglobins
EP4386001A1 (en) Method for estimating hemoglobin a1c level, information processing apparatus, and computer-readable storage medium
CN110954637A (en) Chromatograph and quantitative method of chromatographic analysis
JP7443815B2 (en) How to classify chromatograms using statistical methods
US20240210366A1 (en) Data processing method and device for chromatogram, chromatographic device, and recording medium
JP7171960B1 (en) Method for detecting glycated hemoglobin, method for measuring glycated hemoglobin, liquid chromatography device and program
JP3911867B2 (en) Chromatogram analyzer
CN116794207A (en) Method for measuring hemoglobin F

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220418

R151 Written notification of patent or utility model registration

Ref document number: 7070137

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151